Hyperferritinemia: Not Always Hemochromatosis

A Critical Care Perspective on Differential Diagnosis and Management

Dr Neeraj Manikath, Claude.ai

Abstract

Background: Hyperferritinemia is frequently encountered in critical care settings, yet its interpretation remains challenging for clinicians. While hereditary hemochromatosis is often the first consideration, the majority of cases in critically ill patients stem from inflammatory conditions, hemophagocytic lymphohistiocytosis (HLH), liver disease, or secondary iron overload.

Objective: To provide a comprehensive framework for the differential diagnosis and management of hyperferritinemia in critical care, emphasizing practical clinical approaches and diagnostic strategies.

Methods: Narrative review of current literature with emphasis on critical care applications and diagnostic algorithms.

Results: Hyperferritinemia represents a complex clinical scenario requiring systematic evaluation of inflammatory markers, liver function, iron studies, and specific disease entities. Early recognition of HLH and appropriate differentiation from other causes can be life-saving.

Conclusions: A structured approach to hyperferritinemia interpretation, incorporating clinical context and targeted investigations, improves diagnostic accuracy and therapeutic outcomes in critical care settings.

Keywords: Hyperferritinemia, Critical Care, Hemophagocytic Lymphohistiocytosis, Iron Overload, Differential Diagnosis

Introduction

Ferritin, an intracellular iron storage protein, serves as both an iron biomarker and an acute-phase reactant. In critical care medicine, hyperferritinemia (typically defined as serum ferritin >300 μg/L in men and >200 μg/L in women) is encountered in up to 60% of intensive care unit admissions¹. While hereditary hemochromatosis represents the classical cause of severe iron overload, it accounts for less than 5% of hyperferritinemia cases in the critical care setting².

The diagnostic challenge lies in distinguishing between inflammatory hyperferritinemia, which predominates in critical illness, and true iron overload states. This distinction has profound therapeutic implications, as inappropriate iron chelation therapy can be detrimental in inflammatory conditions, while delayed recognition of conditions like hemophagocytic lymphohistiocytosis (HLH) can be fatal³.

Pathophysiology of Ferritin Elevation

Iron-Related Mechanisms

True iron overload: Increased iron absorption or parenteral iron administration
Cellular iron sequestration: Inflammatory cytokines upregulate ferritin synthesis independently of iron status
Tissue damage: Release of intracellular ferritin from damaged hepatocytes, muscle, or other tissues

Inflammatory Pathways

Interleukin-1β, tumor necrosis factor-α, and interferon-γ stimulate ferritin gene transcription through iron-regulatory proteins, resulting in ferritin elevation that may exceed 10,000 μg/L in severe inflammatory states⁴.

🔍 Clinical Pearl: The magnitude of ferritin elevation often correlates with inflammatory intensity rather than iron burden. Ferritin >10,000 μg/L should prompt immediate evaluation for HLH, severe sepsis, or massive tissue necrosis.

Differential Diagnosis Framework

1. Inflammatory Hyperferritinemia

Clinical Context:

Sepsis and systemic inflammatory response syndrome
Autoimmune disorders (Still's disease, systemic lupus erythematosus)
Malignancy
Severe burns or trauma

Laboratory Characteristics:

Elevated C-reactive protein and erythrocyte sedimentation rate
Normal or low transferrin saturation (<45%)
Elevated inflammatory cytokines
Normal or elevated hepcidin levels

🎯 Diagnostic Hack: Calculate the ferritin-to-ESR ratio. A ratio >15 suggests non-inflammatory causes, while <15 points toward inflammatory etiology⁵.

2. Hemophagocytic Lymphohistiocytosis (HLH)

HLH represents a hyperinflammatory syndrome with dysregulated immune activation, carrying mortality rates exceeding 50% without treatment⁶.

HLH-2004 Diagnostic Criteria:

Fever ≥38.5°C
Splenomegaly
Cytopenia (≥2 lineages)
Hypertriglyceridemia (≥265 mg/dL) and/or hypofibrinogenemia (≤150 mg/dL)
Hemophagocytosis in bone marrow, spleen, or lymph nodes
Low or absent NK cell activity
Ferritin ≥500 μg/L
Elevated soluble CD25 (≥2400 U/mL)

🚨 Critical Recognition Point: The H-Score calculator provides probability assessment for HLH diagnosis. A score >169 indicates >90% probability of HLH⁷.

Ferritin Patterns in HLH:

Typically >10,000 μg/L (sensitivity 90%, specificity 65%)
Progressive elevation over days to weeks
Often >50,000 μg/L in fulminant cases

3. Liver Disease-Associated Hyperferritinemia

Mechanisms:

Hepatocellular damage with ferritin release
Impaired ferritin clearance
Associated inflammatory responses
Concurrent iron overload in alcoholic liver disease

Clinical Patterns:

Acute hepatitis: Ferritin 1,000-10,000 μg/L with markedly elevated transaminases
Chronic liver disease: Moderate elevation (500-2,000 μg/L) with evidence of synthetic dysfunction
Hepatocellular carcinoma: Often >1,000 μg/L with α-fetoprotein elevation

🔧 Management Hack: In acute liver failure, ferritin levels >6,000 μg/L correlate with poor prognosis and may guide transplant listing urgency⁸.

4. Iron Overload Syndromes

Primary Iron Overload (Hereditary Hemochromatosis)

Clinical Features:

Family history
Progressive organ dysfunction (liver, heart, pancreas, joints)
Bronze skin pigmentation
Typically presents in middle age

Laboratory Markers:

Transferrin saturation >45% (most sensitive early marker)
Ferritin elevation proportional to iron burden
Elevated liver iron concentration
HFE gene mutations (C282Y, H63D)

Secondary Iron Overload

Causes:

Multiple blood transfusions (>20 units)
Chronic hemolytic anemias
Ineffective erythropoiesis (thalassemia, myelodysplastic syndrome)
Parenteral iron administration

🎓 Teaching Point: One unit of packed red blood cells contains approximately 200-250 mg of iron. The body can only eliminate 1-2 mg of iron daily, making transfusion-related iron overload inevitable after repeated transfusions.

Diagnostic Algorithm

Initial Assessment

Clinical Context Evaluation
- Acute vs. chronic presentation
- Inflammatory signs and symptoms
- Family history
- Medication and transfusion history
Laboratory Panel
- Complete blood count with differential
- Comprehensive metabolic panel
- Liver function tests
- Iron studies (ferritin, serum iron, TIBC, transferrin saturation)
- Inflammatory markers (CRP, ESR)
- Coagulation studies

Second-Tier Investigations

Based on initial findings:

If Inflammatory Pattern:

Blood cultures and infectious workup
Autoimmune markers (ANA, RF, complement)
Triglycerides and fibrinogen
Soluble CD25 and ferritin kinetics
Bone marrow examination if HLH suspected

If Iron Overload Suspected:

HFE genetic testing
Liver MRI for iron quantification
Echocardiogram and ECG
Ophthalmologic examination
Endocrine evaluation (glucose, thyroid function)

🔍 Diagnostic Pearl: The ferritin-to-AST ratio can help distinguish causes. Ratios >10 suggest iron overload, while <5 typically indicate inflammatory conditions⁹.

Management Strategies

Inflammatory Hyperferritinemia

Primary focus: Treat underlying condition
Avoid iron supplementation even if other iron parameters suggest deficiency
Monitor: Serial ferritin levels should decline with resolution of inflammation
Consider: Anti-inflammatory therapy in autoimmune conditions

HLH Management

Immediate: HLH-94 or HLH-2004 protocol
- Dexamethasone 10 mg/m² daily
- Etoposide 150 mg/m² twice weekly
- Cyclosporine A in selected cases
Supportive care: Aggressive management of cytopenia, coagulopathy
Trigger identification: Treat underlying infections, malignancies

Iron Overload Treatment

Primary Hemochromatosis:

Phlebotomy: Gold standard therapy
- Initial: 500 mL weekly until ferritin <50 μg/L
- Maintenance: Every 2-4 months
Iron chelation: Reserved for patients unable to tolerate phlebotomy

Secondary Iron Overload:

Chelation therapy:
- Deferoxamine: 20-40 mg/kg/day subcutaneous
- Deferiprone: 75-100 mg/kg/day oral
- Deferasirox: 20-40 mg/kg/day oral
Monitoring: Regular assessment of iron burden and chelator toxicity

⚠️ Management Warning: Never initiate iron chelation therapy in patients with active infections or severe inflammatory conditions, as it may worsen outcomes by impairing immune function.

Clinical Pearls and Practice Points

Ferritin Interpretation Hacks

The 1000 Rule: Ferritin >1000 μg/L in the absence of blood transfusion or obvious inflammation warrants iron overload evaluation
The Kinetics Clue: Rapidly rising ferritin suggests inflammation or HLH; slowly progressive elevation suggests iron accumulation
The Saturation Sign: Transferrin saturation >45% with any ferritin elevation requires hemochromatosis consideration

Red Flags Requiring Immediate Action

Ferritin >10,000 μg/L with fever and cytopenia (HLH until proven otherwise)
Ferritin >5,000 μg/L in acute liver failure (consider transplant evaluation)
New-onset heart failure with hyperferritinemia (evaluate for iron cardiomyopathy)

Common Pitfalls

Over-relying on ferritin alone: Always interpret in clinical context
Missing HLH: High index of suspicion in critically ill patients with extreme hyperferritinemia
Inappropriate iron studies: Avoid iron studies during acute inflammation when possible
Premature iron chelation: Can be harmful in inflammatory states

Special Considerations in Critical Care

COVID-19 and Hyperferritinemia

The COVID-19 pandemic has highlighted the significance of hyperferritinemia in viral infections. Ferritin levels >1,000 μg/L are associated with increased mortality and may indicate cytokine storm syndrome¹⁰.

Drug-Induced Hyperferritinemia

Several medications can cause ferritin elevation:

Iron supplementation (oral and parenteral)
Immunosuppressive agents
Certain antibiotics (chloramphenicol)
Chemotherapy agents

Pediatric Considerations

Normal ferritin values are age-dependent in children. HLH has a bimodal distribution with peaks in infancy and adolescence, requiring high clinical suspicion¹¹.

Future Directions and Research

Biomarker Development

Hepcidin: Emerging as a key regulator of iron homeostasis
Glycosylated ferritin: May better reflect iron stores than total ferritin
Ferritin isoforms: L-ferritin vs. H-ferritin ratios in different disease states

Therapeutic Advances

Novel iron chelators with improved safety profiles
Targeted therapies for HLH (anti-IL-1, anti-IL-6 agents)
Personalized medicine approaches based on genetic profiling

Conclusions

Hyperferritinemia in critical care represents a diagnostic challenge requiring systematic evaluation and clinical correlation. While hereditary hemochromatosis remains important, inflammatory conditions, HLH, and liver disease account for the majority of cases in critically ill patients. Early recognition of life-threatening conditions like HLH, combined with appropriate management of underlying causes, can significantly improve patient outcomes.

The key to successful management lies in understanding the pathophysiologic basis of ferritin elevation, applying structured diagnostic algorithms, and avoiding common pitfalls such as inappropriate iron chelation in inflammatory states. As our understanding of iron metabolism and inflammatory pathways continues to evolve, more targeted therapeutic approaches will likely emerge.

References

Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel disease. Gut. 2004;53(8):1190-1197.
Girelli D, Nemeth E, Swinkels DW. Hepcidin in the diagnosis of iron disorders. Blood. 2016;127(23):2809-2813.
Ramos E, Kautz L, Rodriguez R, et al. Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice. Hepatology. 2011;53(4):1333-1341.
La Rosee P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465-2477.
Fautrel B, Zing E, Golmard JL, et al. Proposal for a new set of classification criteria for adult-onset Still disease. Medicine (Baltimore). 2002;81(3):194-200.
Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613-2620.
Schmidt LE, Dalhoff K. Serum phosphate is an early predictor of outcome in severe acetaminophen-induced hepatotoxicity. Hepatology. 2002;36(3):659-665.
Adams PC, Barton JC. How I treat hemochromatosis. Blood. 2010;116(3):317-325.
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846-848.
Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr. 2007;166(2):95-109.

Conflicts of Interest

The authors declare no conflicts of interest.

Funding

No funding was received for this review.

Monday, June 30, 2025

Hyperferritinemia In icu